PreDiCT-TB project highlighted in parliamentary debate on ending tuberculosis. Further information available by clicking on the following links: https://news.liverpool.ac.uk/2018/06/08/inspirational-tb-research-highlighted-at-parliamentary-debate https://goo.gl/dL77Yn
On 25th April 2018: Gerry Davies and Justin Green will be supported by PreDiCT-TB project manager Philip Whitehead as they head to Brussels this Thursday to present a wide-ranging summary of the 5-year …
PreDiCT-TB Coordinator Justin Green, talks about the project on World TB Day
Because it’s World TB Day I’d like to share my story on how I started with TB research and what it has brought so far. Especially on this day I realise the implications …
Gerry Davies talks TB and the work of the PreDiCT-TB Consortium on World TB Day.
The American Society for Pharmacology and Therapeutics (ASCPT) is enacting its 5-year strategic plan through member-lead scientific networks. The Quantitative Pharmacology Network, chaired by Anne Heatherington from Pfizer, has led the “Influence and …
On the 7th and 8th of March the PanACEA held its inaugural meeting in Cape Town, South Africa, attended by a number of the PreDiCT-TB team including Gerry, Wilber, Derek and Stephen. The meeting …
The ASM Conference on Tuberculosis will take place in New York from 1st – 4th April 2017. Further details are available here.
PreDiCT-TB discussed in the latest IMI Newsletter.
The 47th World Conference on Lung Health will take place in Liverpool, UK from 26th – 29th October 2016. Further details are available here.
Dr Justin Green, PreDiCT-TB co-coordinator, is a clinical trials physician at GSK, based in London. Having spent 15 years in the UK NHS, including being awarded a PhD in TB Immunology from Imperial College London, he received his infectious diseases specialist training certification in 2009. He now works in the Diseases of the Developing World group in a number of teams focusing mainly on TB and malaria collaborating with external bodies such as academic institutions and NGOs.
PreDiCT-TB brings together twenty-one leading European research partners in tuberculosis from both Industry and Academia
The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115337, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution.
The communication contained within this site reflects the author’s view and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained therein.
